Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy

被引:63
作者
Dustin, L. B. [1 ]
Bartolini, B. [2 ]
Capobianchi, M. R. [2 ]
Pistello, M. [3 ,4 ,5 ]
机构
[1] Univ Oxford, Kennedy Inst Rheumatol & Peter Medawar Bldg Patho, Oxford, England
[2] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Virol Lab, Rome, Italy
[3] Univ Pisa, Virol Unit, Pisa Univ Hosp, Pisa, Italy
[4] Univ Pisa, Virol Sect, Pisa, Italy
[5] Univ Pisa, Retrovirus Ctr, Dept Translat Res, Pisa, Italy
关键词
Broadly reactive neutralizing antibodies; Cell culture-derived HCV; Direct antiviral agents; Drug resistance; Genotype; Hepatitis C virus; Host response monitoring drug resistance; Pathogenesis; Quantitative molecular assays; IMMUNE-RESPONSES; HCV INFECTION; CLINICAL UTILITY; NATURAL-HISTORY; INNATE IMMUNITY; GLOBAL-CONTROL; RNA; RESISTANCE; QUANTIFICATION; PERFORMANCE;
D O I
10.1016/j.cmi.2016.08.025
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Hepatitis C virus (HCV) is a major global health burden accounting for around 170 million chronic infections worldwide. Since its discovery, which dates back to about 30 years ago, many details of the viral genome organization and the astonishing genetic diversity have been unveiled but, owing to the difficulty of culturing HCV in vitro and obtaining fully susceptible yet immunocompetent in vivo models, we are still a long way from the full comprehension of viral life cycle, host cell pathways facilitating or counteracting infection, pathogenetic mechanisms in vivo, and host defences. Here, we illustrate the viral life cycle into cells, describe the interplay between immune and genetic host factors shaping the course of infection, and provide details of the molecular approaches currently used to genotype, monitor replication in vivo, and study the emergence of drug-resistant viral variants. (C) 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:826 / 832
页数:7
相关论文
共 91 条
[1]   Standardization and performance evaluation of "modified" and "ultrasensitive" versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia [J].
Amendola, Alessandra ;
Bloisi, Maria ;
Marsella, Patrizia ;
Sabatini, Rosella ;
Bibbo, Angela ;
Angeletti, Claudio ;
Capobianchi, Maria Rosaria .
JOURNAL OF CLINICAL VIROLOGY, 2011, 52 (01) :17-22
[2]   Characterization of low- and very-low-density hepatitis C virus RNA-containing particles [J].
André, P ;
Komurian-Pradel, F ;
Deforges, S ;
Perret, M ;
Berland, JL ;
Sodoyer, M ;
Pol, S ;
Bréchot, C ;
Paranhos-Baccalà, G ;
Lotteau, V .
JOURNAL OF VIROLOGY, 2002, 76 (14) :6919-6928
[3]   The past, present and future of neutralizing antibodies for hepatitis C virus [J].
Ball, Jonathan K. ;
Tarr, Alexander W. ;
McKeating, Jane A. .
ANTIVIRAL RESEARCH, 2014, 105 :100-111
[4]   Determining the Involvement and Therapeutic Implications of Host Cellular Factors in Hepatitis C Virus Cell-to-Cell Spread [J].
Barretto, Naina ;
Sainz, Bruno, Jr. ;
Hussain, Snawar ;
Uprichard, Susan L. .
JOURNAL OF VIROLOGY, 2014, 88 (09) :5050-5061
[5]   HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study [J].
Bartolini, Barbara ;
Selleri, Marina ;
Garbuglia, Anna Rosa ;
Giombini, Emanuela ;
Taibi, Chiara ;
Lionetti, Raffaella ;
D'Offizi, Gianpiero ;
Capobianchi, Maria R. .
JOURNAL OF CLINICAL VIROLOGY, 2015, 72 :60-65
[6]   Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV plus daclatasvir: A case study using ultra deep pyrosequencing [J].
Bartolini, Barbara ;
Lionetti, Raffaella ;
Giombini, Emanuela ;
Sias, Catia ;
Taibi, Chiara ;
Montalbano, Marzia ;
D'Offizi, Gianpiero ;
McPhee, Fiona ;
Hughes, Eric A. ;
Zhou, Nannan ;
Ippolito, Giuseppe ;
Garbuglia, Anna Rosa ;
Capobianchi, Maria R. .
JOURNAL OF CLINICAL VIROLOGY, 2015, 66 :38-43
[7]   Host-targeting agents in the treatment of hepatitis C: A beginning and an end? [J].
Baugh, James M. ;
Garcia-Rivera, Jose A. ;
Gallay, Philippe A. .
ANTIVIRAL RESEARCH, 2013, 100 (02) :555-561
[8]   Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing [J].
Bergfors, Assar ;
Leenheer, Daniel ;
Bergqvist, Anders ;
Ameur, Adam ;
Lennerstrand, Johan .
ANTIVIRAL RESEARCH, 2016, 126 :81-89
[9]   Chronic hepatitis C virus infection: genotyping and its clinical role [J].
Bowden, D. Scott ;
Berzsenyi, Mark D. .
FUTURE MICROBIOLOGY, 2006, 1 (01) :103-112
[10]   SOFOSBUVIR-BASED TREATMENT UNDER REAL LIFE CONDITIONS IN GERMANY (THE SOFGER TRIAL) [J].
Buggisch, P. ;
Sarrazin, C. ;
Mauss, S. ;
Hinrichsen, H. ;
Simon, K. -G. ;
Vermehren, J. ;
Hueppe, D. ;
Petersen, J. .
JOURNAL OF HEPATOLOGY, 2015, 62 :S622-S622